In an ongoing phase I/II trial SAVE study (NCT05360160) designed for KMT2Ar, NPM1-m, and NUP98r leukemias, MRD was reported to be undetectable in three of seven treated patients (43%) with the combination. This evidence concerns the gene NPM1 and leukemia.